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Deep Brain Stimulation of the 
subthalamic nucleus does not 
negatively affect social cognitive 
abilities of patients with 
Parkinson’s disease
Ivan Enrici  1,2,3, Antonia Mitkova4, Lorys Castelli5, Michele Lanotte6, Leonardo Lopiano6 & 
Mauro Adenzato2,3,5
Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN) is a treatment option 
for patients with advanced idiopathic PD successful at alleviating disabling motor symptoms. 
Nevertheless, the effects of STN-DBS on cognitive functions remain controversial and few studies 
have investigated modification of social cognitive abilities in patients with PD treated with STN-DBS. 
Here we expanded the typically-investigated spectrum of these abilities by simultaneously examining 
emotion recognition, and both affective and cognitive Theory of Mind (ToM). By means of a cross-
sectional study, 20 patients with PD under dopaminergic replacement therapy, 18 patients with PD 
treated with STN-DBS, and 20 healthy controls performed the Ekman 60-Faces test, the full version 
of the Reading the Mind in the Eyes test, and the Protocol for the Attribution of Communicative 
Intentions. There were no differences between the PD groups (treated and not treated with STN-DBS) 
on any of the social cognitive tests. Our results suggest that patients with PD who are treated with 
STN-DBS do not experience detrimental effects on their social cognitive abilities. The present study, the 
first one examining a wide spectrum of social cognitive abilities after DBS of the STN, suggests that this 
surgical procedure can be considered safe from this standpoint.
Parkinson’s Disease (PD) is a neurodegenerative disease associated with clinical symptoms that include bradykin-
esia, rigidity, resting tremor, and postural instability. Although PD is characterized primarily by motor symptoms, 
cognitive impairment and psychiatric disorders can be also observed even in the earliest stages of the disease1, 2. 
Cognitive deficits in patients with PD result from dopamine depletion and are attributed to disruption of the 
reciprocal loops between the striatum and structures in the prefrontal cortex. Therefore, individuals with PD may 
experience impairments in various cognitive domains that primarily depend on the frontal lobes. Furthermore, 
patients with PD have impaired performance in social cognitive tasks, such as recognition of emotional facial 
expression and those requiring Theory of Mind (ToM), i.e. the ability to explain and predict other people’s mental 
states3–5.
Chronic bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN) is a treatment option 
for patients with advanced idiopathic PD. STN-DBS is specifically indicated in patients for whom long-term 
pharmacological treatment has failed, and is remarkably successful at alleviating disabling motor symptoms6. 
Nevertheless, the effects of STN-DBS on cognitive functions, mood, and behaviour remain controversial, and 
experimental findings in this domain are sometimes contradictory7–11. Although cognitive difficulties such as 
moderate declines in executive functions, verbal memory, and fluency tasks have been reported, studies with 
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large patient cohorts indicate that STN-DBS does not produce general cognitive declines12, 13. However, clini-
cal and psychiatric issues, such as depression8, 14 and (hypo)mania15 have been reported following STN-DBS. 
Furthermore, DBS may also result in social maladjustment and aggravation of other pre-existing psychiatric 
disorders16, 17.
Previous research has examined emotional processing following STN-DBS, focusing primarily on subjec-
tive emotions and arousal, as well as emotion recognition17 (see Mallet et al., 2007 for a review). The effect of 
STN-DBS on emotion processing and its reported effects on cognition and mood are likely related to the role of 
the STN in the basal ganglia network. The DBS modifies dopaminergic transmission in the basal ganglia, affecting 
the limbic, associative, and motor networks via highly organised circuits18, 19. These basal ganglia circuits are com-
prised of both cortical (orbitofrontal cortex, temporal sulcus, temporal poles, cingulate gyrus and prefrontal cor-
tex) and subcortical regions (amygdala and ventral striatum), and correspond with structures that also mediate 
social cognition20, 21. Furthermore, the basal ganglia networks also directly target the prefrontal cortex, including 
the dorsolateral prefrontal cortex and the anterior cingulate cortex.
Several studies have investigated social cognitive domains in patients with PD, whereas very few studies have 
tested modification of these domains by directly comparing patients with PD who are either treated or not treated 
with STN-DBS. In particular, no study has simultaneously investigated the effects of STN-DBS on (1) emotion 
recognition, i.e. reading facial expressions of emotion, (2) affective ToM (emotion representation), i.e., the ability 
to represent others’ emotions, and (3) cognitive ToM, i.e. the ability to represent others’ beliefs and intentions22, 23.
The aim of the present study was to examine the effects of STN-DBS on social cognitive abilities, particularly 
on emotion recognition, affective ToM, and cognitive ToM. This study aim at expanding knowledge regard-
ing social cognitive abilities by testing patients’ abilities in both emotion recognition and representation, as 
well as by assessing both affective ToM and cognitive ToM. The rationale for investigating these features was to 
increase understanding regarding the complex clinical outcomes following STN-DBS, especially in relation to the 
non-motor symptoms of PD.
Results
Cognitive functioning assessment and demographic measures. The cognitive functioning 
assessment and demographic data for the DRT-PD, STN-DBS-PD, and HC groups are presented in Table 1. 
Experimental groups were matched for demographic variables such as age, education, and gender. Regarding the 
cognitive functioning assessment, experimental groups did not differ based on MMSE scores, whereas significant 
group differences occurred for the FAB scores (H(2) = 8.221, p = 0.016). Pairwise Mann–Whitney tests revealed 
significant differences between DRT-PD and STN-DBS-PD (U = 103.5, p = 0.023, η2 = 0.132) groups, as well as 
STN-DBS-PD and HC (U = 267.5, p = 0.009, η2 = 0.172) groups, with participants in the STN-DBS-PD group 
performing worse than participants in the DRT-PD and HC groups.
Social cognitive assessment. The difference in emotion recognition performance between DRT-PD, 
STN-DBS-PD and HC groups (i.e., Ekman total score, as well as the basic emotions of sadness, happiness, anger, 
disgust, fear, and surprise), affective ToM, and cognitive ToM are presented in Table 2. Significant group effects 
occurred for the Ekman 60-Faces total score (H(2) = 6.824, p = 0.033), and for anger (H(2) = 7.094, p = 0.029) and 
surprise (H(2) = 11.129, p = 0.004), but not for sadness, happiness, disgust, or fear. Moreover, significant group 
differences occurred for both the CInt (H(2) = 19.469, p < 0.001) and PhC (H(2) = 7.275, p = 0.026) conditions 
of the PACI, and for the RME experimental score (H(2) = 11.861, p = 0.003), but not for the RME control score.
Pairwise Mann–Whitney tests revealed no statistically significant differences between the DRT-PD and 
STN-DBS-PD groups for social cognitive dimensions, with the exception of anger (U = 250, p = 0.041), for which 
the STN-DBS-PD group performed better than the DRT-PD group. However, this difference disappeared after 
correction for multiple comparisons, suggesting a spurious effect.
Pairwise Mann–Whitney tests corrected for multiple comparisons revealed significant differences between the 
DRT-PD and HC groups for the CInt condition (U = 347, p < 0.001, η2 = 0.395), and the RME experimental score 
(U = 315, p = 0.001, η2 = 0.242). There were also significant differences between the STN-DBS-PD and HC groups 
for Ekman-surprise (U = 273.5, p = 0.005, η2 = 0.197), CInt condition (U = 297, p < 0.001, η2 = 0.308), and RME 
experimental scores (U = 275, p = 0.005, η2 = 0.203).
DRT-PD n = 20 STN-DBS-PD n = 18 HC n = 20
Age (years) 59.75 (5.81) (range = 50–70)
60.89 (6.26) 
(range = 41–70)
60 (7.47) 
(range = 45–71)
Education (years) 7.65 (2.52) 7.44 (3.85) 9.35 (3.34)
Gender (M:F) 10:10 9:9 10:10
MMSE 28.75 (1.04) 28.86 (1.39) 29.27 (1.06)
FAB 17.13 (1.12) 15. 94 (1.66)a,b 17.34 (0.80)
Table 1. Cognitive functioning assessment and demographic measures. Significant group effects found (a) 
between STN-DBS-PD vs. DRT-PD groups and (b) between STN-DBS-PD vs. HC groups. DRT-PD = patients 
with PD receiving dopaminergic replacement therapy; FAB = Frontal Assessment Battery; HC = healthy 
controls; MMSE = Mini Mental State Examination; PD = Parkinson’s disease; STN-DBS PD = patients with PD 
who were treated with deep brain stimulation of the subthalamic nucleus (STN-DBS).
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In order to account for the possible effects of FAB performance on social cognitive measures, we performed 
further analyses using a non-parametric analysis of covariance, Quade’s rank analysis24. After statistically con-
trolling for the FAB scores, the previously described significant group effects persisted.
The differences in performance between the two groups of patients with PD for the neuropsychological, psy-
chiatric and, clinical measures are presented in Tables 3 and 4. No significant group effects occurred for the 
neuropsychological measures, with the exception of the phonemic verbal fluency score (U = 66, p = 0.001, 
η2 = 0.292), for which patients in the DRT-PD group performed better than patients in the STN-DBS-PD group.
Furthermore, the patient groups were well-matched based on the clinical variables, with the exceptions of the 
LEDD (U = 102, p = 0.036, η2 = 0.137), for which patients in the DRT-PD group took a higher dosage compared 
to patients in the STN-DBS-PD group.
In order to investigate the possible relationships between social cognitive (Ekman 60-Faces, PACI, and 
RME) and psychiatric (BDI, STAI, and Apathy Evaluation Scale) measures, we analysed bivariate correlations 
in the two groups of patients with PD, between each dimension (see Table 5 in the supplementary materials). 
For the DRT-PD group, there were significant correlations only between STAI measures and the CInt condition 
(STAI-X1, τb = −0.559, p = 0.002 and STAI-X2, τb = −0.517, p = 0.004), between STAI-X1 and the PhC condi-
tion (τb = −0.417, p = 0.020) and between BDI measures and the CInt condition (τb = −0.361, p = 0.044). For the 
STN-DBS-PD group, there were significant correlations between STAI-X1 and the CInt condition (τb = −0.506, 
p = 0.005), RME (τb = −0.440, p = 0.014), and surprise (τb = −0.391, p = 0.035), as well as between STAI-X2 and 
Ekman total scores (τb = −0.401, p = 0.022) and surprise (τb = −0.432, p = 0.019). Lastly, significant correlations 
occurred between the Apathy Evaluation Scale scores and Ekman total scores (τb = −0.397, p = 0.033), as well as 
between the Apathy Evaluation Scale scores and happiness (τb = −0.417, p = 0.047).
Maximum 
score
DRT-PD 
n = 20
STN-DBS-PD 
n = 18 HC n = 20
Emotion recognition
Ekman 60-Faces total score 60 43 (5.93) 43.89 (6.40) 48.15 (6.74)
Ekman-sadness 10 6.45 (1.96) 6.33 (1.64) 7.2 (1.70)
Ekman-happiness 10 9.65 (0.81) 9.56 (0.78) 9.65 (0.67)
Ekman-anger 10 6.15 (2.11) 7.56 (1.29) 7.75 (1.86)
Ekman-disgust 10 8 (1.95) 7.89 (1.71) 8.3 (2.03)
Ekman-fear 10 4.30 (2.30) 4.33 (2.77) 5.3 (2.88)
Ekman-surprise 10 8.45 (1.57) 8.22 (1.93) 9.6 (0.82)a
Cognitive ToM (PACI task)
Communicative intention 9 6.15 (1.93) 6.06 (2.3) 8.3 (1.08)a,b
Physical causality (control) 9 7.10 (2) 5.94 (2.9) 7.95 (1.67)
Affective ToM
RME 36 19.65 (4.44) 19.44 (4.87) 24.15 (4.65)a,b
RME (control) 36 34.60 (1.23) 34.39 (1.65) 34.65 (1.39)
Table 2. Social cognitive measures. Significant group effects found (a) between STN-DBS-PD vs. HC groups, 
and (b) between DRT-PD vs. HC groups. DRT-PD = patients with PD receiving dopaminergic replacement 
therapy; HC = healthy controls; PACI = Protocol for the Attribution of Communicative Intentions; 
PD = Parkinson’s disease; RME = Reading the Mind in the Eyes Test; ToM = Theory of Mind; STN-DBS 
PD = patients with PD who were treated with deep brain stimulation of the subthalamic nucleus (STN-DBS).
DRT-PD n = 20 STN-DBS-PD n = 18 Mann-Whitney U-test
Corsi’s Block-Tapping Test 4.76 (0.67) 4.58 (0.48) U = 163 p = 0.633
Attentional matrices 47.01 (7.31) 43.11 (7.65) U = 132.5 p = 0.167
Raven’s Coloured Progressive Matrices 30.51 (4.34) 31.53 (3.44) U = 202.5 p = 0.515
Bisyllabic word repetition test 4.13 (0.71) 4.06 (0.94) U = 182.5 p = 0.942
Paired-associate learning 13.24 (2.91) 12.09 (3.51) U = 132.5 p = 0.363
Trail Making Test, Part B 107.20 (136.98) 120.56 (82.29) U = 232 p = 0.133
NCST - categories 5.80 (0.41) 5.89 (0.32) U = 196 p = 0.654
NCST - errors 5.25 (3.19) 3.50 (2.64) U = 122.5 p = 0.093
NCST - perseverations 2.40 (1.85) 2.00 (1.88) U = 163 p = 0.633
Phonemic verbal fluency 39.95 (7.72) 31.67 (6.02) U = 66 p = 0.001
Category verbal fluency 21.64 (3.18) 22.83 (15.97) U = 108.5 p = 0.057
Table 3. Neuropsychological measures. DRT-PD = patients with PD receiving dopaminergic replacement 
therapy; HC = healthy controls; NCST = Nelson Modified Card Sorting Test; PD = Parkinson’s disease; 
RME = Reading the Mind in the Eyes Test; STN-DBS-PD = patients with PD who were treated with deep brain 
stimulation of the subthalamic nucleus (STN-DBS).
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In addition, in the two groups of patients with PD, we investigated possible correlations between social cogni-
tive measures (Ekman 60-Faces, PACI, and RME), dopaminergic pharmacological treatment (LEDD), duration 
of illness, and severity of the disease (UPDRS III Off) (see Table 5 in the supplementary materials). There were no 
statistically significant correlations, except for correlations between sadness and duration of illness (τb = −0.401, 
p = 0.041), and between anger and UPDRS III Off scores (τb = −0.420, p = 0.036) in the STN-DBS-PD group, 
as well as between UPDRS III Off scores and CInt (τb = 0.434, p = 0.014), and PhC (τb = 0.455, p = 0.011) in the 
DRT-PD group.
Finally, for exploratory purpose, we performed bivariate correlations between social cognitive and neuropsy-
chological measures in the two groups of patients with PD (see Tables 6 and 7 in the Supplementary Materials).
Discussion
The main aim of the present paper was to investigate the effects of STN-DBS on the social cognitive abilities of 
patients with PD. Our results strongly suggest that STN-DBS does not negatively affect social cognitive abilities 
of patients with PD. We expanded the typically investigated spectrum of social cognitive abilities by investi-
gating emotion recognition, affective ToM (emotion representation), and cognitive ToM. There were no differ-
ences between the PD groups on any of the social cognitive tasks. DRT-PD, STN-DBS-PD and HC groups were 
matched for age, gender, and education, as well as for general cognitive functioning, as assessed by MMSE scores. 
In addition, the two PD groups were well-matched for duration of illness, and severity of the disease. No signif-
icant differences between the two PD groups occurred for psychiatric (depression, anxiety, and apathy) or neu-
ropsychological scales, with the exception of phonemic fluency. The phonemic fluency score indicated impaired 
ability in the STN-DBS-PD group compared to the DRT-PD and HC groups, which is a well-documented out-
come of STN-DBS13. There was no correlation between social cognition tasks and LEDD.
Emotion recognition. Our results show that STN-DBS, when combined with optimal medical treatment, 
does not result in impairment of emotion recognition in patients with PD. We found no differences between the 
PD groups nor on Ekman 60-Faces total score nor on any of Ekman basic emotion, whereas only Ekman-surprise 
differed between the STN-DBS-PD and HC groups, with participants in the STN-DBS-PD group performing 
worse than participants in the HC groups.
Previous research suggests that patients with PD experience impaired facial emotion expression recognition; 
however, the results are inconclusive regarding the degree and selectivity of emotion recognition impairments25. 
Impaired recognition of disgust has been described in both un-medicated and medicated patients with PD26. 
Other authors have investigated the relationships with neuropsychiatric and neuropsychological symptoms, again 
yielding mainly inconclusive results27.
The effects of STN-DBS on recognition of facial emotion expressions have yielded contrasting findings, 
likely due to different study methods. However, the overall results suggest that STN-DBS may affect the ability 
to recognise negative facial expressions, in particular anger28, and disgust29, 30, as well as fear and sadness31–33. 
In contrast, Mondillon, et al.34 found no impairment in emotion recognition in patients with STN-DBS-PD 
who were evaluated while receiving both dopaminergic and DBS therapies (Stim On-Med On condition). 
Moreover, Albuquerque, et al.35 reported no differences in emotion recognition in patients with advanced PD 
after STN-DBS, based on comparisons of the ability to recognize emotions before and one year after surgery. It is 
important to note that previous studies have administered an emotion recognition task that uses pictures of the 
Ekman 60-Faces Test31–33, 36, showing the pictures for 3 sec. In the present study, we chose not to use a specified 
presentation duration, in order to reduce the demand on attention and working memory. Moreover, our version 
DRT-PD n = 20 STN-DBS-PD n = 18 Mann-Whitney U-test
BDI 13.05 (6.66) 11.61 (6.05) U = 146.5 p = 0.461
STAI-X1 46.47 (10.42) 41.22 (10.00) U = 125 p = 0.169
STAI-X2 44.95 (10.63) 41.61 (8.43) U = 134.5 p = 0.271
Apathy Evaluation Scale 12.84 (5.56) 11.88 (3.59) U = 145 p = 0.616
LEDD 1074.45 (431.60) 760.44 (384.29) U = 102 p = 0.036
LEDD-Dopa 973.13 (427.15) 735.39 (356.64) U = 113.5 p = 0.081
LEDD-DA 100.84 (98.10) 47.28 (55.18) U = 115 p = 0.092
H&Y Off 2.39 (0.53) 2.94 (0.70) U = 200 p = 0.055
H&Y On 1.42 (0.58) 2.06 (1.08) U = 193.5 p = 0.088
UPDRS III Off 33.13 (8.83) 39.53 (13.77) U = 198 p = 0.133
UPDRS III On 12.18 (4.58) 12.53 (6.46) U = 155 p = 0.935
Duration of illness (years) 11.50 (2.98) (range = 8–20)
12.56 (3.03) 
(range = 10–20) U = 218 p = 0.276
Table 4. Psychiatric and clinical measures. BDI = Beck Depression Inventory; DRT-PD = patients with PD 
receiving dopaminergic replacement therapy; H&Y = Hoehn and Yahr scale; LEDD = L-dopa equivalent daily 
dose; LEDD-Dopa = LEDD-dopaminergic portion; LEDD-DA = LEDD-dopamine agonists; PD = Parkinson’s 
disease; STAI = State Trait Anxiety Inventory; STN-DBS-PD = patients with PD who were treated with deep 
brain stimulation of the subthalamic nucleus (STN-DBS); UPDRS = Unified Parkinson’s Disease Rating Scale.
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of the Ekman 60-Faces Test is comprised of 10 stimuli for each basic emotion, whereas previous studies have used 
a modified version of the test that consists of fewer stimuli for each emotion.
Our results confirm the findings by Mondillon, et al.34, who found no impairment of facial expression recog-
nition in patients with STN-DBS-PD in an optimal medication and stimulation condition, compared to an HC 
group. The authors of this study did not assess the patients for facial expression recognition pre-STN-DBS and did 
not have a control group of patients with PD, therefore, we cannot make comparisons for all aspects of the study.
Affective ToM. Our findings show that patients with PD who are treated with STN-DBS do not experience 
detrimental effects on affective ToM. No differences between the PD groups on the RME were found, whereas the 
performance on the RME differed between both the PD groups and HC, with participants in the STN-DBS-PD 
and DRT-PD groups performing worse than participants in the HC group.
Consistent with most previous studies, we observed impairments in emotion representation in patients with 
PD. We have previously suggested that the decline in this ability depends on the spatiotemporal progression of 
dopamine depletion in patients with PD, indicating that emotion representation abilities may be impaired at more 
advanced stages of PD5, 25, 37. These declines may be mediated by dopaminergic depletion-induced hypostimu-
lation of the ventromedial prefrontal cortex by the frontostriatal loops, since the ventromedial prefrontal cortex 
contributes to emotion representation.
Two previous studies have assessed affective ToM in patients with STN-DBS-PD, using the RME38, 39, how-
ever, these studies yielded contrasting results. McIntosh, et al.39 administered the RME to patients with early PD, 
who were randomised to receive either DRT (n = 7) or STN-DBS surgery (n = 9). Due to small sample size, the 
authors did not compare the two groups directly and did not suggest any conclusions regarding the compari-
son. Investigating the effect of treatment type (DRT vs. STN-DBS) and treatment state (ON/OFF) tasks, these 
authors found no significant effects of therapy on RME performance. Peron, et al.38 correlated RME performance 
to changes in glucose metabolism by conducting fludeoxyglucose positron emission tomography scans of 13 
patients with PD at both three months prior to and three months post-STN-DBS surgery. The authors examined 
RME performance using a reduced 17 item version of the test, and compared the performance of the PD group 
pre- and post-surgery with that of an HC group (n = 13). They found no significant difference between preoper-
ative PD and HC results, whereas postoperative patients performed significantly worse than either preoperative 
PD or HC groups.
The discrepancies between our results and those of Peron, et al.38 may have resulted from different study 
methods. As previously discussed, most studies that have used the RME in patients with PD have found impaired 
emotion representation. Peron, et al.38 found that the pre-surgery performance of patients with PD did not dif-
fer from that of participants in the HC group, indicating that these abilities were preserved in their PD group. 
Furthermore, there are methodological differences regarding the versions of the RME administered, with Peron, 
et al.38 using a shorter 17 item test, whereas we used the full version comprised of 36 items. It has been suggested 
that using short versions of the RME is problematic, as mild or sub-threshold impairments in affective ToM may 
not be detected25, 37.
Cognitive ToM. The present study is the first examination of cognitive components of ToM after DBS of the 
STN in patients with PD, and our results show that STN-DBS has no detrimental effects on cognitive ToM. No 
differences between the PD groups on PACI tasks were found, whereas the performance on CInt differed between 
both the PD groups and HC, with participants in the STN-DBS-PD and DRT-PD groups performing worse than 
participants in the HC group.
The experimental protocol that we used to study intention attribution was initially developed for a series of 
fMRI studies aimed at exploring the theoretical classification of intentions40–45. The results of these studies strongly 
implicate the prefrontal cortices in the ability to understand the intentions of people involved in communicative 
interactions (i.e. cognitive ToM). The prefrontal cortices are critical to the neuropathology of PD, as well as in STN 
networks, and are also implicated in cognitive ToM; therefore, effects of STN-DBS on this latter ability cannot be 
excluded. Furthermore, numerous reports support impairment of cognitive ToM in patients with PD37, 46, leading 
to the question of whether an existing impairment changes as a result of stimulation. Thus, the present findings 
corroborate the hypothesis that tasks requiring the comprehension of others’ intention may be impaired in both 
PD groups and, more importantly, suggest that STN-DBS has no detrimental effects on cognitive ToM.
Conclusion
STN-DBS surgery is commonly used to treat the motor symptoms of patients with PD. Research has begun to 
investigate the effects of STN-DBS on mood and cognition, and factors such as subtle differences in electrode 
placement, stimulation parameters, patient vulnerability prior to STN-DBS, and dopamine dose changes may 
influence the outcomes of STN-DBS in patients with PD. Since non-motor effects of STN-DBS have the potential 
for large impacts on patient quality of life, it is essential to assess possible effects of STN-DBS on every aspect of 
cognition.
STN-DBS may also provide a useful model for studying the role of the STN in emotional processes and ToM20, 38. 
Most previous studies focus on emotion recognition following STN-DBS, however, the present study investigated dif-
ferent facets of social cognition, namely emotion recognition, affective ToM, and cognitive ToM.
The present study has two main limitations. Firstly, the sample size is relatively small, and future studies should 
aim to replicate our findings using larger samples. Secondly, we used only the MMSE and FAB as neuropsycholog-
ical measures to compare the two groups of PD with the HC group. Despite these limitations, the present study is 
the first investigation of the effects of STN-DBS on social cognition, using measures to assess emotion recognition 
and representation, as well as both cognitive and affective ToM. We found no specific effects of STN-DBS on 
emotion recognition, cognitive ToM and affective ToM. The results of the present study contribute to knowledge 
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regarding the cognitive safety of STN-DBS treatment. Our results support that STN-DBS is safe in relation to the 
social cognitive domain and does not have detrimental effects on the social cognitive abilities investigated.
Materials and Methods
Ethics statement. Written informed consent was obtained from all participants. The study was approved 
by the San Giovanni Battista University Hospital’s ethics committee and was conducted in accordance with the 
Declaration of Helsinki.
Participants. By means of a cross-sectional study, 20 consecutive patients with PD under dopaminergic 
replacement therapy (DRT), 18 patients with PD treated with STN-DBS, and 20 healthy controls (HC) with neg-
ative neurological and psychiatric history were enrolled in the study. All patients were consecutively referred to 
the neurology unit of Turin University Hospital for standard care visits. Inclusion criteria included a diagnosis of 
idiopathic PD, and age ≥40 years. Exclusion criteria for all groups of participants were the presence of dementia 
or severe cognitive impairment (Mini Mental State Examination, MMSE ≤ 26), and presence of other neurolog-
ical or psychiatric disorders, such as severe depression as assessed using a psychological interview and the Beck 
Depression Inventory (BDI)47, which is a validated measure for depression symptoms in patients with PD48.
All patients received their daily optimal dopamine replacement therapies (L-dopa preparations, and/or dopa-
mine receptor agonists).
Motor evaluations. Motor evaluations were performed according to the Unified Parkinson’s Disease Rating 
Scale, Part III (UPDRS-III)49. Scores were measured at baseline (after overnight withdrawal of all dopaminergic 
medication) and after administration of a loading dose of L-dopa (calculated as 1.5× the usual L-dopa equivalent 
morning dose).
In the first clinical group (DRT-PD), UPDRS scores were measured during two conditions: on-medication 
(Med On) and off-medication (Med Off). The second group (STN-DBS-PD) was assessed during four different 
conditions: with stimulation switched on after overnight medication withdrawal (Stim On-Med Off); 60 min after 
switching off stimulation, after overnight medication withdrawal (Stim Off-Med Off); with stimulation switched 
off and about 40 minutes after the administration of L-dopa therapy, at the same dose used for the preoperative 
test (Stim Off-Med On); and undergoing both stimulation and L-dopa therapy condition (Stim On-Med On). 
In the present study we analysed the UPDRS Off conditions, i.e., the Med Off condition for DRT-PD group and 
Stim Off-Med Off for STN-DBS-PD, in order to compare the severity of the disease between the two PD groups. 
Furthermore, Hoehn and Yahr (H&Y)50 scale was administered in order to assess the progression of motor symp-
toms in both On and Off conditions. L-dopa equivalent daily doses (LEDD) were calculated according to com-
monly established standard conversions51.
Neurosurgery. The surgical procedure52 involved bilateral electrode implantation in the STN, which was 
accomplished during two independent surgeries. Anatomical targeting was performed using magnetic res-
onance imaging (MRI)/computed tomography image fusion. During surgery, clinical effects were evaluated 
using electro-physiological recordings and microstimulation, in order to achieve the best possible lead place-
ment. Postoperative MRI was performed in order to confirm electrode positioning and to exclude surgical 
complications.
Eligibility criteria for DBS included diagnosis of idiopathic PD, presence of severe motor fluctuations and/
or drug-related dyskinesias, and clinical response to L-dopa treatment for motor symptoms. Moreover, patients 
were <70 years of age, did not have dementia and/or relevant psychiatric comorbidities, and did not have relevant 
atrophy or focal abnormalities on brain MRI. The patient selection was performed based on the Core Assessment 
Program for Surgical Interventional Therapies in Parkinson’s Disease (CAPSIT-PD)53.
Background neuropsychological and psychiatric assessments. The MMSE54 and the Frontal 
Assessment Battery (FAB)55, 56 were administered to all participants prior to social cognitive tasks, as a prelim-
inary screening for global cognitive and executive functioning. In addition, a standardised neuropsychological 
battery of tests10 was administered to both DRT-PD and STN-DBS-PD groups, in order to evaluate reason-
ing, memory, attention, and executive functions. Reasoning was assessed using Raven’s Coloured Progressive 
Matrices57. Short term memory for verbal (bi-syllabic word repetition test) and visuospatial components (Corsi’s 
Block Tapping Test)58 were assessed, and long term memory was assessed using the Wechsler memory scale sub-
test, which is a paired-associate learning test59. Attention and executive functions were assessed using attentional 
matrices58, the Trail Making Test, Part B60, the Nelson Modified Card Sorting test61, 62, as well as phonemic58 and 
category verbal fluency tasks59.
Psychiatric assessments included evaluation of apathy anxiety and depression using the Apathy Evaluation 
Scale63, the State Trait Anxiety Inventory (STAI)64, in particular (STAI-X1) and (STAI-X2), and the BDI47.
Social cognition tasks. The DRT-PD, STN-DBS-PD, and HC groups performed three social cognitive tasks: 
the Ekman 60-Faces Test for emotion recognition, the 36-item full version of the Reading the Mind in the Eyes 
(RME) test for affective ToM, and the Protocol for the Attribution of Communicative Intentions (PACI) for cog-
nitive ToM.
The ability to recognise basic facial emotions was evaluated using the Italian version of the Ekman 60-Faces 
Test65, 66. This task assesses both overall emotion recognition and basic emotion detection. It consists of 60 black 
and white pictures that portray the faces of 10 actors, each displaying the six basic emotions (happiness, surprise, 
anger, disgust, fear, and sadness). A computerised sequence of slides containing a facial emotion picture was 
administered to participants, requiring them to select the label that best described the facial expression in the 
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picture. The labels were visible throughout testing and participants were allowed as much time as they needed to 
verbally make their selection. No feedback was given throughout testing.
The RME67 is an advanced test of affective ToM (emotion representation) that consists of 36 partial pictures 
of a face depicting only the eye region. The task was presented on a computer screen. For each photograph, 
participants were asked to choose one of four words that best described what the character was thinking or feel-
ing. One correct and three distractor words were presented for each item. Explanations of the labels were given 
when requested by participants, using the definitions provided by the Italian validation of the task68. The score 
was calculated by counting the total number of correct choices (maximum score 36). In order to exclude visual 
impairment, we administered the RME gender-recognition control task, which required participants to identify 
the gender of the character in the photograph.
The PACI is an intention attribution task40, 42, 69, 70 that distinguishes between social and physical interactions, 
and was administered as a measure of cognitive ToM. A series of 18 comic strips was presented to participants, 
representing two different conceptual categories: communicative intentions (CInt), and physical causality (PhC). 
The CInt condition consisted of nine stories that each portrayed two characters involved in a communicative 
interaction (e.g. a person asking for a glass of water and obtaining it from another person). The PhC condition 
consisted of nine stories that each depicted a physical interaction between objects (e.g. a ball blown by a gust 
of wind knocks over and breaks bottles of water), and did not require ToM abilities. Each story consisted of 
three pictures (development phase) that appeared consecutively on the screen, followed by a set of four options 
(response phase), and participants selected the most appropriate and logical story ending. The correct picture rep-
resented a probable and congruent outcome resulting from the development phase, while the incorrect pictures 
represented an improbable or incongruent effect. In order to avoid working memory overload and inaccuracies 
due to slowed information processing speed, patients were allowed an unlimited duration of time to respond, and 
all pictures remained on the screen while participants completed the story. Examples of the stories can be found 
at the following web address: www.psych.unito.it/csc/pers/adenzato/pdf/stn_dbs_pd.pdf.
Procedure. The neuropsychological assessment and the experimental tasks were performed under optimal 
clinical conditions for all participants. In particular, patients in the DRT-PD group, who were not treated with 
STN-DBS, were assessed in the Med On condition, while patients in the STN-DBS group were assessed in the 
Stim On-Med On condition. Patients in the STN-DBS-PD group were evaluated at least six months after surgery, 
in order to minimise microlesion effects71, with a mean follow up of 1.72 (±1.18) years.
Statistical analyses. Statistical analyses were conducted using SPSS version 24.0 for Windows. There were 
a limited number of participants in each group and significant deviations from normality of variable distribu-
tion, as assessed by Shapiro-Wilk’s tests (p < 0.05); therefore, non-parametric methods were used (Kruskal-Wallis 
H-test, Mann-Whitney U-test, and Kendall’s tau-b correlation coefficient). Comparisons of the three independent 
groups were performed using the Kruskal-Wallis H-test. When the Kruskal–Wallis test yielded a significant dif-
ference, pairwise Mann–Whitney tests were conducted in order to determine specific differences with a signifi-
cance level of 0.05, Bonferroni-corrected for multiple comparisons. The effect size was determined by calculating 
Eta squared (η2).
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